There is a rhetorical move that anyone with five minutes of exposure to the wellness industry will recognise. The form is: "Mainstream medicine is fifteen to thirty years behind what we already know. By the time the studies catch up, this practice will be standard. Until then, we are simply earlier than the consensus."
The move is powerful because it contains a real phenomenon — clinical translation lag — wrapped around a deflection. Distinguishing the legitimate version from the rhetorical one matters, because the same phrase performs very different work in the two contexts.
The legitimate phenomenon
The translation gap between published research and clinical practice is real and has been measured.
The most-cited figure comes from Andrew Balas and Suzanne Boren's 2000 chapter, which estimated that it takes an average of 17 years for biomedical research findings to be widely adopted in clinical practice. The figure has been challenged, refined, and updated, but the underlying observation has held: useful findings often languish for one or two decades after publication before being broadly applied.
Concrete cases populate the history of medicine.
Helicobacter pylori and peptic ulcers. Barry Marshall and Robin Warren demonstrated in 1982 that most peptic ulcers were caused by a bacterial infection rather than by stress and stomach acid. The proposal was dismissed by the medical establishment for nearly a decade. Marshall famously drank a flask of H. pylori to demonstrate the causal pathway. The standard of care shifted only in the mid-1990s, and Marshall and Warren received the Nobel Prize in 2005 — twenty-three years after the original observation.
Atrial fibrillation and stroke prevention. Anticoagulation for AF-related stroke prevention was demonstrated in the late 1980s. Adoption into routine practice for eligible patients lagged by 10–15 years, and underuse persisted into the 2010s.
Surgical hand hygiene. Ignaz Semmelweis's 1840s demonstration that physician hand-washing reduced post-partum mortality was rejected by the medical establishment of his time. He died in an asylum in 1865. The germ theory, including hand hygiene, became standard practice only in the late 19th century.
These cases are real. The translation lag is a real feature of medicine, and the rhetorical move that points at it is not pure fabrication.
The rhetorical move
The version of the claim used to defend unsupported practices has a recognisable structure.
"What I am doing is ahead of the published literature. The studies will eventually validate it. The fact that no studies currently support it is therefore not an argument against it."
The structure is unfalsifiable in the moment. Any current criticism can be deflected to a future state in which the criticism will look outdated. The person making the claim is positioned as a visionary; the critics, as defenders of an out-of-date consensus.
The move is most often deployed by:
- Supplement industry figures making molecular or hormonal claims
- Promoters of alternative cancer therapies
- Advocates of unproven longevity interventions
- Sellers of devices and protocols without published efficacy data
The form of the move is identical to the legitimate cases. The substance is different.
Heuristics for distinguishing
Several markers tend to separate the legitimate translation gap from the rhetorical deflection.
The legitimate cases involve published findings that the field has not adopted. Marshall and Warren had published, peer-reviewed work demonstrating the bacterial mechanism. The case for H. pylori was sitting in the literature for over a decade, waiting for adoption. The rhetorical version typically points at absent published findings — claims that have not been demonstrated rather than claims that have been demonstrated and ignored.
The legitimate cases involve specific, testable mechanisms. H. pylori causes ulcers via specific pathways that could be demonstrated. Anticoagulation prevents AF-related stroke via specific mechanisms with measurable endpoints. The rhetorical version often involves vague mechanisms — "supports cellular optimisation," "balances the endocrine system," "boosts mitochondrial function" — that resist falsification because they don't specify what would count against them.
The legitimate cases are championed by researchers who continue producing data. Marshall kept doing experiments and engaging with critics. The rhetorical version is typically championed by figures whose primary output is books, podcasts, and product lines rather than primary research.
The legitimate cases involve a specific, identifiable point of resistance. With H. pylori, the resistance came from a particular gastroenterology consensus committed to a different explanatory model. The resistance was specific, identifiable, and eventually overcome by evidence. The rhetorical version typically involves a diffuse "mainstream" that is conveniently never named.
The legitimate cases produce convergent independent replication. Marshall and Warren's findings were eventually replicated by researchers around the world, in different populations, with different methodologies. The rhetorical version typically does not converge — the supporting evidence comes from the same circle of advocates, year after year, without independent replication.
The right disposition
For someone trying to navigate this:
- The translation gap is real. Discount slightly for it. A finding that has been demonstrated by independent groups, published, and not yet broadly adopted may be worth attending to ahead of the consensus.
- The rhetorical version is not. A claim that depends on the absence of published evidence as proof of its novelty is a claim with no available test of its truth.
- The asymmetry is important. The legitimate cases will eventually be vindicated by data. The rhetorical cases will not, and the same line will continue to be used to defend them indefinitely.
- The honest position on any specific unsupported claim is usually "the evidence is currently not strong enough to recommend this," with no rhetorical move available to bridge the gap.
"Extraordinary claims require extraordinary evidence." — Carl Sagan, paraphrasing Marcello Truzzi.
The corollary that fits this case: extraordinary claims that depend on the inadequacy of conventional evidence to support them have rarely turned out, on reflection, to be extraordinary. They have usually turned out to be the kind of claim that should have required ordinary evidence and didn't get any.
